期刊
NATURE
卷 515, 期 7528, 页码 568-+出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nature13954
关键词
-
资金
- National Institutes of Health [K08 AI091663]
- Kure It Research Grant [UL1TR000124, P01 CA168585, U54 CA119347, R01 CA170689]
- Ressler Family Fund
- Dr Robert Vigen Memorial Fund
- Wesley Coyle Memorial Fund
- Garcia-Corsini Family Fund
- Stand Up To Cancer-Cancer Research Institute Cancer Immunology Dream Team Translational Research Grant [SU2C-AACR-DT1012]
- Merck Sharp and Dome
- Adaptive Biotechnologies
- V Foundation-Gil Nickel Family Endowed Fellowship in Melanoma Research
- Spanish Society of Medical Oncology for Translational Research in Reference Centers
- [P30 CA16042]
Therapies that target the programmed death-1 (PD-1) receptor have shown unprecedented rates of durable clinical responses in patients with various cancer types(1-5). One mechanism by which cancer tissues limit the host immune response is via upregulation of PD-1 ligand (PD-L1) and its ligation to PD-1 on antigen-specific CD8(+) T cells (termed adaptive immune resistance)7. Here we show that pre-existing CD8(+) T cells distinctly located at the invasive tumour margin are associated with expression of the PD-1/PD-Li immune inhibitory axis and may predict response to therapy. We analysed samples from 46 patients with metastatic melanoma obtained before and during anti-PD-1 therapy (pembrolizumab) using quantitative immunohistochemistry, quantitative multiplex immunofluorescence, and nextgeneration sequencing for T-cell antigen receptors (TCRs). In serially sampled tumours, patients responding to treatment showed proliferation of intratumoral CD8(+) T cells that directly correlated with radiographic reduction in tumour size. Pre-treatment samples obtained from responding patients showed higher numbers of CD8-, PD-1- and PD-L1-expressing cells at the invasive tumour margin and inside tumours, with close proximity between PD-1 and PD-L1, and a more clonal TCR repertoire. Using multivariate analysis, we established a predictive model based on CD8(+) expression at the invasive margin and validated the model in an independent cohort of 15 patients. Our findings indicate that tumour regression after therapeutic PD-1 blockade requires pre-existing CD8 T cells that are negatively regulated by PD-1 /PD-Li-mediated adaptive immune resistance.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据